HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to stop head and neck cancer from returning
Disease control OngoingThis study tests whether adding the drug pembrolizumab (Keytruda) to targeted radiation therapy can help people with head and neck cancer that has come back or is a new tumor. About 86 adults whose cancer cannot be removed by surgery will be randomly assigned to get radiation alo…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE2 • Sponsor: RTOG Foundation, Inc. • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC
-
New cocktail of drugs shows promise for tough head and neck cancers
Disease control OngoingThis study tests whether combining several drugs can shrink tumors in adults with head and neck cancer that has come back or spread. Participants receive up to three antibodies that help the immune system fight cancer, block tumor growth signals, and cut off blood supply to tumor…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 12, 2026 12:07 UTC
-
New antibody combo shows promise against hard-to-treat cancers
Disease control OngoingThis early-phase trial tests an experimental antibody called GEN1042, alone or with the cancer drug pembrolizumab (with or without chemotherapy), in adults with advanced solid tumors like lung, colon, melanoma, head and neck, or pancreatic cancer. The main goals are to check safe…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC
-
New drug combo aims to shrink tough head and neck tumors
Disease control OngoingThis study tests whether adding an experimental drug (INBRX-106) to a standard immunotherapy (pembrolizumab) works better than the standard drug alone for people with advanced head and neck cancer that has spread or come back. About 410 adults whose tumors have a specific marker …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE2, PHASE3 • Sponsor: Inhibrx Biosciences, Inc • Aim: Disease control
Last updated Jun 08, 2026 13:18 UTC
-
New cancer drug AB598 enters early safety testing
Disease control OngoingThis early-phase study tests a new drug called AB598, alone or with other treatments, in about 40 people with advanced solid tumors (like lung, bladder, or breast cancer). The main goal is to check if the drug is safe and tolerable. Participants must have measurable tumors and be…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Jun 03, 2026 13:13 UTC
-
New drug cocktail shows promise in shrinking head and neck tumors before surgery
Disease control OngoingThis study tests whether giving immune-boosting drugs before surgery can help shrink head and neck cancer tumors. About 80 adults with advanced but removable cancer will receive either nivolumab alone or combined with relatlimab or ipilimumab. Researchers will monitor side effect…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated Jun 03, 2026 12:04 UTC